New York is currently home to 4507 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
Recruiting
The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to inform CF research, help design CF clinical trials and support the development of new treatments for people with CF who do not take CFTR modulators. Another goal of this study is to learn about research... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/24/2025
Locations: The Cystic Fibrosis Center of Western New York, Buffalo, New York
Conditions: Cystic Fibrosis
Centralized Screening Unit (CSU) at Montefiore-Einstein
Recruiting
This study proposes to increase Lung-cancer screening (LCS) in the Bronx, New York. Despite strong evidence that Lung-cancer screening (LCS) can reduce Lung cancer (LCa) deaths, low-dose computed tomography (LDCT) referral rates by clinicians are very low and there is poor adherence with LCS by patients. Both provider and patient barriers may be amenable to systemic improvements in support, coordination and infrastructure for screening. The investigator team hypothesizes that the implementation... Read More
Gender:
ALL
Ages:
Between 50 years and 77 years
Trial Updated:
03/24/2025
Locations: Montefiore Medical Center's New York City Research and Improvement Networking Group (NYC RING), Bronx, New York
Conditions: Lung Cancer
Promoting Equitable Access to Language Services in Health and Human Services
Recruiting
This is a community-based study that will engage community and health care stakeholders to develop, implement, and evaluate a Health Literacy (HL)-informed, culturally- and linguistically- sensitive approach to improving language access services for patients with limited English proficiency (LEP) to promote health equity and reduce disparities in preventive health services use and health outcomes in New York City (NYC). This study will have a total of 4 phases that include a preparatory work pha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Health + Hospitals Diagnostic/Treatment Centers, New York, New York
Conditions: Appropriate Use of Language Across Services
Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors
Recruiting
This study is to evaluate the safety, tolerability, and PK profiles of RMC-6291 and RMC-6236 in adults with KRAS G12C-mutated solid tumors.
Gender:
ALL
Ages:
Between 18 years and 125 years
Trial Updated:
03/24/2025
Locations: Columbia University, New York, New York
Conditions: Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
Recruiting
The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).
Gender:
ALL
Ages:
Between 28 days and 17 years
Trial Updated:
03/24/2025
Locations: Omeros Investigational Site, New York, New York
Conditions: Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Recruiting
The primary objectives of Cohort A Phase 1b are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepatocellular Carcinoma (HCC) and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of TTI-101 as a single agent. The primary objectives of Cohort A Phase 2 are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent at the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Memorial Sloan Kettering Cancer Center - New York, New York, New York
Conditions: Hepatocellular Carcinoma
Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
Recruiting
The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing; however, the evidence regarding the ideal treatment for this often vulnerable and frail patient cohort is limited. Although the benefit of concomitant chemotherapy has been reported to decrease in elderly HNSCC patients based on the MACH-NC meta-analysis, it remains unknown whether state-of-the art radiotherapy techniques such as intensity-modulated radiotherapy (IMRT), modern supportive treatments and al... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
03/24/2025
Locations: Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: HNSCC, Oral Cavity Cancer, Oropharynx Cancer, Hypopharynx Cancer, Larynx Cancer
Study of INCB123667 in Subjects With Advanced Solid Tumors
Recruiting
This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with anticancer therapies in participants with selected advanced or metastatic solid tumors. This study will consist of 2 parts. In Part 1, INCB123667 will be administered as monotherapy and in Part 2, INCB123667 will be administered in combination with anticancer therapies of intere... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Solid Tumors
Telephone-Based Support Programs for People With Epilepsy
Recruiting
This is a two-arm randomized controlled trial to compare telephone-based depression self-management (UPLIFT) to telephone-based support groups (BOOST). A sample of 120 English- and Spanish-speaking people with epilepsy (PWE) with elevated depressive symptoms will be enrolled. Both interventions are 8-week programs delivered in one-hour weekly sessions to groups of about 6 participants. Changes in depressive symptoms, quality of life and seizures will be assessed over 12 months. The trial will al... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
03/24/2025
Locations: NYU Langone Health, New York, New York
Conditions: Epilepsy
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
Recruiting
This study will test a drug called enfortumab vedotin in participants with a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC). This study will also evaluate what the side effects are and if the drug works to treat NMIBC. A side effect is anything a drug does to your body besides treating your disease. In this study enfortumab vedotin will be put into the bladder using a catheter. A catheter is a thin tube that can be put into your bladder.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York
Conditions: Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma Transitional Cell, Non-muscle Invasive Bladder Cancer, NMIBC
Virtual Neuro-Navigation System for Personalized Community Based TMS
Recruiting
Phase I study of a virtual neuro-navigation package with built-in support for identifying specific "surface-based" targets to optimze TMS treatment.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
03/24/2025
Locations: Columbia Docs, New York, New York
Conditions: Treatment Resistant Depression
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
Recruiting
This study will assess the safety and effectiveness of GORE® CARDIOFORM Septal Occluder in a post approval setting and evaluate the quality of operator education and training and transferability of trial experience to a post-market setting.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/24/2025
Locations: Research Foundation SUNY Buffalo, Buffalo, New York
Conditions: Stroke, PFO - Patent Foramen Ovale